BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18654741)

  • 1. Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.
    Li H; Jin HE; Kim W; Han YH; Kim DD; Chung SJ; Shim CK
    Pharm Res; 2008 Nov; 25(11):2601-12. PubMed ID: 18654741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
    Marchetti S; Oostendorp RL; Pluim D; van Eijndhoven M; van Tellingen O; Schinkel AH; Versace R; Beijnen JH; Mazzanti R; Schellens JH
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3307-13. PubMed ID: 18089724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
    J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Poller B; Wagenaar E; Tang SC; Schinkel AH
    Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential role of ATP-binding cassette transporters in the intestinal transport of rhein.
    Ye L; Lu L; Li Y; Zeng S; Yang X; Chen W; Feng Q; Liu W; Tang L; Liu Z
    Food Chem Toxicol; 2013 Aug; 58():301-5. PubMed ID: 23665409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K; Sane R; Podila L; Taub ME
    J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).
    Lalloo AK; Luo FR; Guo A; Paranjpe PV; Lee SH; Vyas V; Rubin E; Sinko PJ
    BMC Med; 2004 May; 2():16. PubMed ID: 15125776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
    Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
    Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
    Zhang S; Wang X; Sagawa K; Morris ME
    Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
    Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
    Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of probenecid on the biliary excretion of belotecan.
    Namkoong EM; Kim IW; Kim DD; Chung SJ; Shim CK
    Arch Pharm Res; 2007 Nov; 30(11):1482-8. PubMed ID: 18087819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Black ginger extract and its active compound, 5,7-dimethoxyflavone, increase intestinal drug absorption via efflux drug transporter inhibitions.
    Boonnop R; Meetam P; Siangjong L; Tuchinda P; Thongphasuk P; Soodvilai S; Soodvilai S
    Drug Metab Pharmacokinet; 2023 Jun; 50():100500. PubMed ID: 36948091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1.
    Luo FR; Paranjpe PV; Guo A; Rubin E; Sinko P
    Drug Metab Dispos; 2002 Jul; 30(7):763-70. PubMed ID: 12065434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Breast Cancer Resistance Protein (BCRP/ABCG2) on Drug Transport Across Caco-2 Cell Monolayers.
    Kawahara I; Nishikawa S; Yamamoto A; Kono Y; Fujita T
    Drug Metab Dispos; 2020 Jun; 48(6):491-498. PubMed ID: 32193356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil.
    Choi MK; Song IS
    J Pharm Pharmacol; 2012 Aug; 64(8):1074-83. PubMed ID: 22775210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
    Dahan A; Sabit H; Amidon GL
    AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
    Schellens JH; Maliepaard M; Scheper RJ; Scheffer GL; Jonker JW; Smit JW; Beijnen JH; Schinkel AH
    Ann N Y Acad Sci; 2000; 922():188-94. PubMed ID: 11193894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal absorption mechanisms of 2'-deoxy-2'-β-fluoro-4'-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein.
    Liu Y; Liu B; Zhang Y; Peng Y; Huang C; Wang N; Jiang J; Wang Q; Chang J
    Eur J Pharm Sci; 2017 Jul; 105():150-158. PubMed ID: 28487144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment and modulation of forsythiaside absorption with MDCKII cells and validation with in situ intestinal experiment.
    Li YX; Zhang RQ; Peng C
    Eur J Drug Metab Pharmacokinet; 2012 Sep; 37(3):179-86. PubMed ID: 22430364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.